Original ArticleLoading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses
Graphical Abstract
Schematic representation of ex vivo assays performed with formulations based on HLA-A*0201-restricted HIV-peptides and Mannosides co-conjugated to GNPs (P1@HM). P1@HM interaction, process and antigen presentation by DC derived from blood monocytes of HIV+ individuals, promotes T-cell proliferation of autologous lymphocytes obtained from the same HLA-A*0201 HIV-1+ individuals. P1@HM treatment consistently enhances highly functional pro-TH1 cytokines, pro-TH1 chemokines, pro-inflammatory cytokine and several pro-TH2 cytokines as important immune factors that could potentiate a high adjuvant effect in an HIV vaccine context.
Section snippets
Ethics statement
This study received the approval of the Committee of Ethics and Clinical Investigation of the Hospital Clinic Universitari (Barcelona, Spain). All the subjects participating in the study were recruited at the Service of Infectious Diseases & AIDS Unit of this Hospital and gave their informed written consent.
Study individuals
Samples of EDTA-anticoagulated venous blood samples were obtained from 9 chronic asymptomatic HIV-1-infected patients HLA A*0201 positives with baseline CD4+ T cell counts >450 cells/mm3,
Preparation of GNPs bearing the HIV Gag p17 and CMV pp65 immunogenic peptides and mannosides or glucosides
In this work we have loaded gold nanoparticles (GNPs) with HIV-peptides or CMV-peptides and mannosides and challenged them through ex vivo assays with monocyte derived dendritic cells (MDDCs) and autologous lymphocytes from HIV + −infected patients in search for specific T cell responses (Figure 1, A).
GNPs compound were prepared using a well-established methodology. Briefly, KKWK tagged P1 and P2 HLA-A*0201-restricted peptides, from HIV and CMV, respectively (Figure 1, B) were covalently linked
Discussion
We found that MDDCs pulsed with nanoparticles P1@HM or P2@HM exhibit enhanced capacities in stimulating virus antigen-specific CD8+ and CD4+ T-cell proliferation. These results suggest that co-delivery of high mannose ligands (HM) with the HIV peptides antigen coated on GNPs has an enhanced adjuvant effect, inducing strong T cell proliferative responses following ex vivo pulsing and after full maturation of autologous DC, whereas no addition of maturation agents or GNPs without P1 or P2
Acknowledgments
We appreciate the help of L. Liz-Marzan with nanoparticles analysis, advice and preparation of the paper, Cristina Rovira and Carmen Hurtado for their technical assistance in sample processing.
References (68)
- et al.
Approaches to preventative and therapeutic HIV vaccines
Curr Opin Virol
(2016) - et al.
Duration, combination and timing: the signal integration model of dendritic cell activation
Trends Immunol
(2007) - et al.
Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses
Vaccine
(2014) - et al.
Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands
Biomaterials
(2016) - et al.
Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas
Cell
(2010) - et al.
Assembling different antennas of the gp120 high mannose-type glycans on gold nanoparticles provides superior binding to the anti-HIV antibody 2G12 than the individual antennas
Carbohydr Res
(2015) - et al.
Nanotechnology-based systems for the treatment and prevention of HIV/AIDS
Adv Drug Deliv Rev
(2010) - et al.
Nanovaccines for malaria using plasmodium falciparum antigen Pfs25 attached gold nanoparticles
Vaccine
(2015) - et al.
The use of PEGylated poly [2-(N,N-dimethylamino) ethyl methacrylate] as a mucosal DNA delivery vector and the activation of innate immunity and improvement of HIV-1-specific immune responses
Biomaterials
(2010) - et al.
Role of nanotechnology in HIV/AIDS vaccine development
Adv Drug Deliv Rev
(2016)
A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei
Nanomedicine Nanotechnol Biol Med
HIV gp120 receptors on human dendritic cells
Blood
Increasing diversity of animal lectin structures
Curr Opin Struct Biol
Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens
J Control Release
Self-assembling peptide for co-delivery of HIV-1 CD8+ T cells epitope and toll-like receptor 7/8 agonists R848 to induce maturation of monocyte derived dendritic cell and augment polyfunctional cytotoxic T lymphocyte (CTL) response
J Control Release
Cell selective response to gold nanoparticles
Nanomedicine Nanotechnol Biol Med
Gold nanoparticles coated with oligomannosides of HIV-1 glycoprotein gp120 mimic the carbohydrate epitope of antibody 2G12
J Mol Biol
Targeting dendritic cells through gold nanoparticles: a review on the cellular uptake and subsequent immunological properties
Mol Immunol
In vivo delivery of peptides and toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model
J Control Release
Gold manno-glyconanoparticles for intervening in HIV gp120 carbohydrate-mediated processes
Methods Enzymol
HIV vaccines: progress to date
Drugs
Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions
J Int AIDS Soc
Prospects for the control of AIDS by immunizing seropositive individuals
Nature
Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation
Nanomedicine
A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication
Sci Transl Med
Dendritic cell based vaccines for HIV infection: the way ahead
Hum Vaccin Immunother
Decisions about dendritic cells: past, present, and future
Annu Rev Immunol
Development of monocytes, macrophages, and dendritic cells
Science
Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals
PloS One
Strategic role of selected noble metal nanoparticles in medicine
Crit Rev Microbiol
Applications of gold nanoparticles in Nanomedicine: recent advances in vaccines
Mol Basel Switz
Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment
Nano Lett
Gold nanoparticles as carriers for a synthetic Streptococcus Pneumoniae type 14 conjugate vaccine
Nanomedicine
Preparation and immunogenicity of gold glyco-nanoparticles as antipneumococcal vaccine model
Nanomedicine
Cited by (46)
Advances in immunological and theranostic approaches of gold nanoparticles – A review
2023, Inorganic Chemistry CommunicationsImmunomodulatory nanosystems: An emerging strategy to combat viral infections
2023, Biomaterials and BiosystemsCellular interactions and design principles of glyco-gold nanoparticles for drug delivery applications
2023, Gold Nanoparticles for Drug DeliveryApplication of gold nanoparticles in vaccine development
2023, Gold Nanoparticles for Drug DeliveryNano-biomaterials for therapeutic and diagnostic applications
2023, Applications of Multifunctional NanomaterialsNano toolbox in immune modulation and nanovaccines
2022, Trends in BiotechnologyCitation Excerpt :Mycobacterium tuberculosis (MtB) lipids attached to chitosan NPs induce both cell-mediated and humoral immunity leading to enhanced secretion of IgG, IgM, and Th1/Th2 cytokines [123]. Amantadine-coated silver NPs triggered HIV-specific cytotoxic T lymphocyte (CTL) production and eightfold stronger TNF-α production in vivo [124]. Multiwalled carbon nanotubes and silica NPs can both activate the NOD-like receptor (NLR) family pyrin domain-containing 3 (NLRP3) inflammasome leading to uncontrolled pathological inflammation.
Conflicts of interests: The authors have declared that no competing interest exists.
This study was partially supported by grants: FIS PI12/00969, PI15/00480 and PI15/00641, from Plan Nacional de I+D and co-financed by ISCIII-Subdirección General de Evaluación and Fondo Europeo de Desarrollo, Regional (FEDER) RD16/0025/0002, SAF2013-45232-R, SAF2015-66193-R, RIS, and HIVACAT.
RIS: Red Temática Cooperativa de Grupos de Investigación en Sida del Fondo de Investigación Sanitaria (FIS).
HIVACAT: HIV Vaccine Development Program in Catalonia.
IDIBAPS: Institut d'Investigacions Biomèdiques August Pi i Sunyer.
Prior presentation of abstracts at meetings: An abstract regarding this research entitled “Loading Dendritic Cells with Gold Nanoparticles (GNPs) Bearing HIV-peptides and Mannosides Enhance HIV-specific T Cell Responses” has been presented at “HIV Research for Prevention 2016, Chicago, United States, October 17 - 21, 2016”.